Evolent Health, Inc $EVH Holdings Trimmed by Lazard Asset Management LLC

Lazard Asset Management LLC reduced its holdings in Evolent Health, Inc (NYSE:EVH) by 68.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 109,623 shares of the technology company’s stock after selling 239,799 shares during the period. Lazard Asset Management LLC owned about 0.10% of Evolent Health worth $250,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in EVH. Sei Investments Co. boosted its stake in shares of Evolent Health by 50.8% during the 1st quarter. Sei Investments Co. now owns 302,281 shares of the technology company’s stock valued at $689,000 after buying an additional 101,867 shares during the period. State of Wyoming increased its stake in shares of Evolent Health by 54.7% in the first quarter. State of Wyoming now owns 121,751 shares of the technology company’s stock worth $278,000 after acquiring an additional 43,061 shares during the last quarter. First Trust Advisors LP acquired a new position in shares of Evolent Health in the first quarter worth $488,000. Wealthfront Advisers LLC raised its holdings in shares of Evolent Health by 40.8% during the first quarter. Wealthfront Advisers LLC now owns 28,083 shares of the technology company’s stock worth $64,000 after acquiring an additional 8,136 shares in the last quarter. Finally, R Squared Ltd purchased a new stake in shares of Evolent Health during the first quarter worth $26,000.

Analyst Upgrades and Downgrades

A number of brokerages have commented on EVH. Truist Financial downgraded Evolent Health from a “buy” rating to a “hold” rating and set a $7.00 target price on the stock. in a research note on Tuesday, June 30th. Canaccord Genuity Group lifted their price target on Evolent Health from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Weiss Ratings raised Evolent Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Citigroup restated a “sell” rating and issued a $6.75 price objective (up from $5.50) on shares of Evolent Health in a report on Thursday, July 23rd. Finally, TD Cowen cut their price objective on shares of Evolent Health from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.16.

Evolent Health Stock Up 10.3%

Shares of Evolent Health stock opened at $3.96 on Friday. Evolent Health, Inc has a 12-month low of $2.10 and a 12-month high of $10.08. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 2.46. The stock has a 50 day moving average price of $4.75 and a two-hundred day moving average price of $3.72. The stock has a market capitalization of $445.20 million, a P/E ratio of -0.87 and a beta of 0.79.

Evolent Health (NYSE:EVH) last released its quarterly earnings results on Thursday, August 6th. The technology company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. Evolent Health had a negative net margin of 24.08% and a negative return on equity of 3.94%. The company had revenue of $484.50 million for the quarter, compared to analyst estimates of $597.69 million. During the same quarter last year, the firm posted ($0.10) earnings per share. The company’s quarterly revenue was up 46.9% compared to the same quarter last year. Equities analysts expect that Evolent Health, Inc will post -0.16 earnings per share for the current year.

Evolent Health News Summary

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Evolent reported second-quarter adjusted earnings of $0.02 per share, compared with analysts’ expectation of a $0.01 loss and a $0.10 loss in the year-ago quarter. Evolent Health Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Quarterly revenue rose sharply year over year, with management emphasizing continued growth, improving profitability, and stronger cash flow. The earnings call also highlighted a bullish 2027 outlook, supporting the view that Evolent’s expansion is becoming more durable. Evolent Health Q2 2026 Earnings Call Highlights
• Positive Sentiment: The company raised or reaffirmed full-year 2026 revenue guidance at approximately $2.6 billion to $2.7 billion, above the roughly $2.5 billion consensus estimate. That outlook gives investors greater confidence in Evolent’s growth trajectory. Evolent Announces Second Quarter 2026 Results
• Neutral Sentiment: Despite the improved operating performance, Evolent remains unprofitable on a GAAP basis, with a negative net margin, and analysts still project a full-year loss. Execution against the new guidance will therefore remain important.
• Negative Sentiment: The company continues to carry elevated leverage, including a debt-to-equity ratio above 2, which could limit financial flexibility if growth or cash-flow improvements fall short.

Evolent Health Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.